GSK puts up to $815M on the table for Surface Oncology's antibody

GSK puts up to $815M on the table for Surface Oncology's antibody

Source: 
Fierce Biotech
snippet: 

GlaxoSmithKline is stumping up $85 million upfront and up to an extra $730 million in biobucks for Surface Oncology’s early-stage antibody asset.

The drug the U.K. pharma is betting on, known as SRF813, is a fully human, IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells and T cells.